Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial

被引：0
|
作者：
Crippa, A. [1 ]
Mortezavi, A. [2 ]
Discacciati, A. [1 ]
Karlsson, C. T. [3 ]
Strijbos, M. H. [4 ]
Janes, E. [5 ]
Enblad, G. [6 ]
Sautois, B. [7 ]
Ullen, A. [8 ]
Stenner-Liewen, F. [9 ]
Hjalm-Eriksson, M. E. [10 ]
De Maeseneer, D. J. [11 ]
Schatteman, P. [12 ]
Ghysel, C. [13 ]
Oldenburg, J. [14 ]
Lindberg, J. [15 ]
Ost, P. [16 ]
Eklund, M. [17 ]
Gronberg, H. [15 ]
De Laere, B. [18 ]
机构：
[1] Karolinska Inst, Med Epidemiol & Biostat, Stockholm, Sweden
[2] Univ Hosp Basel, Dept Urol, Basel, Switzerland
[3] Umea Univ, Radiat Sci, Oncol, Umea, Sweden
[4] GZA Ziekenhuizen, Med Oncol Dept, Campus Sint Augustinus, Antwerp, Belgium
[5] Sundsvall Hosp, Dept Oncol, Sundsvall, Sweden
[6] Akad Sjukhuset Uppsala, Oncol Dept, Uppsala, Sweden
[7] Ctr Hosp Univ Sart Tilman, Dept Med Oncol, Liege, Belgium
[8] Karolinska Inst, Dept Oncol, Stockholm, Sweden
[9] Univ Spital Basel, Oncol Dept, Basel, Switzerland
[10] Capio St Gorans Hosp, Surg Dept, Stockholm, Sweden
[11] AZ Sint Lucas, Dept Med Oncol, Brugge, Belgium
[12] Onze Lieve Vrouw Clin, Urol, Campus Aalst, Aalst, Belgium
[13] AZ Sint Jan Brugge Oostende AV, Dept Urol, Brugge, Belgium
[14] Univ Oslo, Dept Oncol, Oslo, Norway
[15] Karolinska Inst, Med Epidemiol & Biostat, Stockholm, Sweden
[16] Univ Hosp Ghent, UZ Gent, Radiat Oncol, Ghent, Belgium
[17] Karolinska Inst, Med Epidemiol & Biostat, Huddinge, Sweden
[18] Karolinska Inst, Inst Med Epidemiol & Biostat, Med Epidemiol & Biostat, Solna, Sweden
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1704
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1623P
引用
收藏
页码：S980 / S980
页数：1
相关论文
共 50 条
  • [1] Building confidence in circulating tumour DNA assays for metastatic castration-resistant prostate cancer
    Ng, Sarah W. S.
    Wyatt, Alexander W.
    NATURE REVIEWS UROLOGY, 2021, 18 (05) : 255 - 256
  • [2] Building confidence in circulating tumour DNA assays for metastatic castration-resistant prostate cancer
    Sarah W. S. Ng
    Alexander W. Wyatt
    Nature Reviews Urology, 2021, 18 : 255 - 256
  • [3] PSA trajectories and prediction of time to no-longer clinically benefitting in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
    Broer, L.
    Oldenburg, J.
    Mortezavi, A.
    Lindberg, J.
    Discacciati, A.
    Karlsson, C. T.
    Ullen, A.
    Janes, E.
    Enblad, G.
    Pettersson, L.
    Vigmostad, M. N.
    Hjalm-Eriksson, M. E.
    Olsson, M.
    Schatteman, P.
    Ghysel, C.
    De Laere, B.
    Gronberg, H.
    Ost, P.
    Eklund, M.
    Crippa, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S991 - S992
  • [4] Treatment efficacy of carrelizumab in metastatic castration-resistant prostate cancer, and the significance of circulating tumor DNA fraction
    Zhou, Henan
    Chen, Yanning
    Zhang, Xiaonan
    Sang, Yuanyuan
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2022, 21 (02) : 425 - 432
  • [5] Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer
    Norgaard, Maibritt
    Bjerre, Marianne T.
    Fredsoe, Jacob
    Vang, Soren
    Jensen, Jorgen B.
    De Laere, Bram
    Groenberg, Henrik
    Borre, Michael
    Lindberg, Johan
    Sorensen, Karina D.
    CLINICAL CHEMISTRY, 2023, 69 (04) : 386 - 398
  • [6] Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Agarwal, Neeraj
    Pond, Gregory Russell
    Nagy, Rebecca J.
    Nussenzveig, Roberto H.
    Hahn, Andrew W.
    Sartor, Oliver
    Gourdin, Theodore Stewart
    Nandagopal, Lakshminarayanan
    Ledet, Elisa M.
    Naik, Gurudatta
    Armstrong, Andrew J.
    Wang, Jue
    Bilen, Mehmet Asim
    Gupta, Shilpa
    Grivas, Petros
    Pal, Sumanta K.
    Lanman, Richard B.
    Talasaz, AmirAli
    Lilly, Michael B.
    CANCER, 2019, 125 (09) : 1459 - 1469
  • [7] Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer
    McDaniel, Andrew S.
    Ferraldeschi, Roberta
    Krupa, Rachel
    Landers, Mark
    Graf, Ryon
    Louw, Jessica
    Jendrisak, Adam
    Bales, Natalee
    Marrinucci, Dena
    Zafeiriou, Zafeiris
    Flohr, Penelope
    Sideris, Spyridon
    Crespo, Mateus
    Figueiredo, Ines
    Mateo, Joaquin
    de Bono, Johann S.
    Dittamore, Ryan
    Tomlins, Scott A.
    Attard, Gerhardt
    BJU INTERNATIONAL, 2017, 120 (5B) : E30 - E44
  • [8] Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer
    Yamada, Yasutaka
    Sakamoto, Shinichi
    Rii, Junryo
    Yamamoto, Satoshi
    Kamada, Shuhei
    Imamura, Yusuke
    Nakamura, Kazuyoshi
    Komiya, Akira
    Nakatsu, Hiroomi
    Ichikawa, Tomohiko
    PROSTATE, 2020, 80 (07): : 559 - 569
  • [9] Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC).
    Conteduca, Vincenza
    Wetterskog, Daniel
    Scarpi, Emanuela
    Romanel, Alessandro
    Gurioli, Giorgia
    Jayaram, Anuradha
    Lolli, Cristian
    Schepisi, Giuseppe
    Casadei, Chiara
    Menna, Cecilia
    Wingate, Anna
    Demichelis, Francesca
    De Giorgi, Ugo
    Attard, Gerhardt
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Prognostic and Predictive Utility of Copy Number Variations (CNVS) in Circulating Tumour DNA (CTDNA) from Metastatic Castration-Resistant Prostate Cancer (MCRPC) Patients
    Fettke, Heidi
    Kwan, Edmond M.
    Yu, Jianjun
    Wang, Amy
    Montesinos, Carlos
    Wong, Calvin
    Gong, Xue
    Zheng, Tiantian
    Du, Peter Pan
    Jia, Shidong
    Mant, Andrew
    Parente, Phillip
    Pezaro, Carmel
    Azad, Arun A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 47 - 48
12345